UNITED THERAPEUTICS Corp
UNITED THERAPEUTICS Corp (UTHR): 242 pipeline candidates · 20 upcoming catalysts · ~22 mo cash runway · 378 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
21.6 months
D/E 0.14 · 12% dilution
Lead: Phase 3
242 candidates
20 upcoming, next in ~1d
1 buy · 1243 sells (180d)
A transparent, data-derived signal for UNITED THERAPEUTICS Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$23.4B
Cash
$1.3B
Quarterly Burn
$322.3M
Runway
21.6 mo
Revenue
$781.5M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (242 candidates)
| Drug | Phase |
|---|---|
| [11C]CPPC PET ligand | Phase 1 |
| [18F]PSMA-1007 Injection | Phase 3 |
| [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G. | Phase 1 |
| 10 GE Xenokidney | Phase 1/Phase 2 |
| 111In-J591 | Phase 2 |
| 177Lu girentuximab | Phase 3 |
| 177Lu-J591 | Phase 2 |
| 3,4-Methylenedioxymethamphetamine | Phase 2 |
| 600 mg Ibuprofen | Phase 3 |
| 89Zr-DFO-YS5 | Phase 1 |
Showing 10 of 242 candidates. Sign up for full pipeline.
Upcoming Catalysts (20)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
36.4% historical Phase 2 primary-endpoint success rate (n=228)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
851
Total value held
$25.32B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 5,399,649 | $3.20B |
| vanguard capital management llc | 3,915,078 | $2.32B |
| wellington management group llp | 2,264,247 | $1.34B |
| vanguard portfolio management llc | 2,003,742 | $1.19B |
| state street corp | 1,843,963 | $1.09B |
| renaissance technologies llc | 1,787,019 | $1.06B |
| janus henderson group plc | 1,733,860 | $1.03B |
| geode capital management, llc | 1,233,029 | $729.9M |
| caption management, llc | 1,151,645 | $682.9M |
| susquehanna international group, llp | 862,496 | $511.4M |
Showing top 10 of 851 institutional holders of UNITED THERAPEUTICS Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in UNITED THERAPEUTICS Corp's pipeline?
UNITED THERAPEUTICS Corp (UTHR) has 242 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is UNITED THERAPEUTICS Corp's lead drug candidate?
UNITED THERAPEUTICS Corp's most advanced tracked candidate is [11C]CPPC PET ligand (Phase 1) for ALS.
What is UNITED THERAPEUTICS Corp's next catalyst?
UNITED THERAPEUTICS Corp's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic" — expected June 19, 2026.
What is UNITED THERAPEUTICS Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, UNITED THERAPEUTICS Corp has approximately 21.6 months of cash runway.
What is UNITED THERAPEUTICS Corp's market capitalization?
UNITED THERAPEUTICS Corp's market capitalization is approximately $23.4B.
Get the full picture on UNITED THERAPEUTICS Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.